お知らせ • Dec 02
Uni-Bio Science Group Limited Announces Strategic Cooperation Product with Chongqing Minji Medical Device Co., Ltd
On 2 December 2024, the board of directors of Uni-Bio Science Group Limited announced two significant milestones that demonstrate the Group's continued growth and innovation in the field of medical aesthetics and dermatological solutions. The Group's strategic cooperation product with Chongqing Minji Medical Device Co. Ltd., recombinant collagen dressing, has successfully received Class II medical device approval, with the approval. At the same time, the Group's self-developed medical aesthetics product has been officially launched. These achievements highlight the Group's progress in building a diversified product portfolio across ''biological drugs, medical devices and medical aesthetics'', providing safer and more effective full-cycle skincare solutions for a wide range of patients. Collagen, which is central to the newly approved recombinant collagen dressing, is the most abundant protein in the human body, comprising 25-35% of total protein content. It forms a network of elastic fibers that support the skin's structure, maintain elasticity, and lock in moisture. However, collagen content decreases by approximately 1% annually after maturity (around age 21), leading to a loss of skin firmness and elasticity. Collagen-based products have a wide range of applications, including moisturizing, maintaining the skin barrier, and addressing signs of aging. The launch developed based on proprietary patents of Skbrella FN, marks another key milestone in the Group's efforts to expand its portfolio. Is designed to provide safe, effective solutions for improving skin quality and repair, particularly for patients with damaged or sensitive skin. At the same time, the group is also advancing the development of its SkbrellaTM FN-based medical device. SkbrellaTM FN is a recombinant human fibronectin. Fibronectin plays an essential role in cell migration, adhesion, proliferation, hemostasis, and tissue repair. In the field of medical aesthetics, fibronectin has demonstrated exceptional effectiveness in repairing the skin barrier, making it an ideal solution for treating damaged or sensitive skin, as well as for post-medical procedure care. Looking ahead, the Group will leverage its expertise in dermatology, the robust clinical data from GeneTime, and its established marketing network to accelerate the market penetration of the recombinant collagen dressing and Ji Yan Tai. By integrating these resources, the Group aims to provide comprehensive and full-cycle skincare solution for a wide range of patients, enhancing the specificity and effectiveness of treatments, and strengthening the Group's competitive position in the medical cosmetology and dermatology fields. The Group is well-positioned to capitalize on the growing opportunities in the market. The forecast indicates that the medical aesthetics market will maintain a compound annual growth rate of 10% to 15% between 2024 and 2027. The growth is mainly attributable to the increasing emphasis on medical aesthetics standards and the rise in expenditure in this field, particularly among the middle to high-income groups. These trends fully highlight the Group's innovative solutions' great potential in meeting the growing demand for medical aesthetics. The Board believes that these achievements reflect the Group's steadfast commitment to innovation, strategic execution, and value creation. As the Group continues to execute its strategic vision, it is committed to becoming a leading expert in dermatology in China by leveraging innovation capabilities, clinical expertise, and market insights to drive sustainable growth and long-term success.